NewsBenzingaAbbVie Reports Topline Results From Phase 3 INTREPID Study Evaluating Lutikizumab, Investigational Dual-Variable-Domain IL 1α/1β Antagonist, In Hidradenitis Suppurativa; Study Met Primary Endpoint And 8 Ranked Secondary Endpoints AbbVie Reports Topline Results From Phase 3 INTREPID Study Evaluating Lutikizumab, Investigational Dual-Variable-Domain IL 1α/1β Antagonist, In Hidradenitis Suppurativa; Study Met Primary Endpoint And 8 Ranked Secondary Endpoints Benzinga 2026.10.22 13:08 (GMT+0) Open on Benzinga Other news RedotPay acquires Japanese crypto exchange BTCBOX AI Worries Rattle Markets as Swiss Stocks Outperform Eurozone by Nearly 8 Percentage Points This Month LiveWire Group: Some Technical Issues, But Mostly Demographic Issues (NYSE:LVWR) Weekly Commentary: Need To Talk ByteDance Consolidates AI Apps Again: Xiaoyunque Merged Into Jimeng Initia Discloses Attack Details: MoveVM Cache Vulnerability Led to About $2.7 Million Transferred Out
AI Worries Rattle Markets as Swiss Stocks Outperform Eurozone by Nearly 8 Percentage Points This Month
Initia Discloses Attack Details: MoveVM Cache Vulnerability Led to About $2.7 Million Transferred Out
